Triadic Expectations: Decision Making in the Context of Cancer Treatment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Decisional Regret
研究概览
简要总结
The purpose of this pilot study is to test the feasibility of identifying and interviewing healthcare triads (patients, loved ones and oncologists) in a research study and evaluate the influences of patients' loved ones and oncologists on cancer treatment decision-making. the study team plans to explore concordance or discordance within the triad about the decisions, and also assess decisional conflict, regret and distress. Study methods involve interviewing a total of 75 patients, their loved ones and oncologists about past cancer treatment decisions. Analysis will consist mainly of qualitative content analysis. The investigators do not anticipate risk or safety issues beyond loss of confidentiality or minimal discomfort while discussing a cancer treatment decision.
详细描述
The overall goal of this study is to evaluate the influences of oncologists and patients' loved ones on cancer treatment decision-making. The specific aims are:
AIM 1: Test the feasibility of identifying and interviewing health care triads (patients, loved ones, and oncologists) in a research study about treatment decisions.
AIM 2: Assess perceptions of the decision-making experience from the perspective of three parties within the health care triad (patients, loved ones, and oncologists) and examine the relationships among the triadic perspectives.
AIM 3: Explore concordance or discordance within the triad about cancer treatment decisions and assess decisional conflict, decisional regret, and distress.
This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider. In a few instances, the study team may interview more than one oncologist or loved one per patient.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age;
- •An attending physician or fellow at Duke University Medical Center;
- •Medical, surgical or radiation oncologist;
- •Provides care to patients diagnosed with at least one of the following conditions:
- •Recurrent or refractory Acute Myeloid Leukemia (AML), also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (ANLL);
- •Chronic myeloid leukemia (CML) in blast phase;
- •Non-hodgkin lymphoma (NHL), relapsed or refractory;
- •Acute lymphocytic leukemia (ALL), relapsed or refractory;
- •Metastatic pancreatic cancer;
- •Metastatic colorectal cancer;
- •Metastatic gastro-esophageal cancer;
- •Metastatic Cholangiocarcinoma.
- •Patient Inclusion Criteria:
- •At least 18 years of age;
- •A Duke patient receiving care from an oncology provider who is enrolled in the study;
- •Currently admitted to the Duke University hematological malignancies in-patient service OR being seen at Duke's outpatient GI cancer clinic;
- •Made a cancer treatment decision in the last 3 months;
- •Diagnosed with one of the following:
- •Recurrent or refractory Acute Myeloid Leukemia (AML), also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (ANLL);
- •Chronic myeloid leukemia (CML) in blast phase;
- •Non-hodgkin lymphoma (NHL), relapsed or refractory;
- •Acute lymphocytic leukemia (ALL), relapsed or refractory;
- •Metastatic pancreatic cancer;
- •Metastatic colorectal cancer;
- •Metastatic gastro-esophageal cancer;
- •Metastatic Cholangiocarcinoma.
- •Loved One (friend/family) Inclusion Criteria:
- •At least 18 years of age;
- •Identified by patient as influential in a recent (within 3 months) treatment decision;
- •Able and willing to complete the study interview in person or by telephone.
- •Exclusion for all Subjects:
- •Lacking capacity to give legally effective consent;
- •Does not read or understand English.
排除标准
- 未提供
结局指标
主要结局
Decisional Regret
时间窗: three to four months after treatment decision
This outcome will be measured with an interviewer-administered survey.
Decisional concordance or discordance among members of triads
时间窗: three to four months after treatment decision
This outcome will be measured with an interviewer-administered survey.
次要结局
未报告次要终点